REV1 and cancer: Among the DNA polymerases that are upregulated in cancer cells on targeted therapy13, REV1 carries out translesion synthesis (TLS), a mutagenic process that allows cells to tolerate DNA damage by bypassing lesions that block normal DNA replication, resulting in the introduction of mutations36,37.